Who is sponsoring NCT02524834?

NCT02524834 is sponsored by Rodney A. White, MD.

What drugs are being tested in NCT02524834?

Interventions in NCT02524834: Exclusion of thoracoabdominal lesion, Endovascular Device Implant.

What condition does NCT02524834 study?

NCT02524834 studies Aortic Disease.

Is NCT02524834 still recruiting?

NCT02524834 is currently withdrawn. Last updated 6 May 2025.

Last reviewed 2025-05-06 · How we verify

NCT02524834

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis

Withdrawn NA Last updated 6 May 2025

What this trial tests

NA trial testing Exclusion of thoracoabdominal lesion in Aortic Disease. Withdrawn.

Timeline

29 May 2015

Primary endpoint
18 February 2025

18 February 2025

Quick facts

Lead sponsor	Rodney A. White, MD
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	29 May 2015
Primary completion	18 February 2025
Estimated completion	18 February 2025
Sites	1 location across United States

Drugs / interventions tested

Exclusion of thoracoabdominal lesion
Endovascular Device Implant

Conditions studied

Aortic Disease — all drugs for Aortic Disease →

Sponsor

Rodney A. White, MD

Who can join

Adults 21 to 90, any sex, with Aortic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an early feasibility study that investigates the outcome of selected patients with complex thoracoabdominal aortic lesions who are suitable for endovascular (within the vessel) repair with a physician-modified Medtronic Thoracic Valiant stent graft. The Medtronic Valiant System includes a Valiant Thoracic Stent Graft, a self-expanding, tubular end prosthesis which is modified/customized by the Investigators to fit the patient's anatomy. The device is constructed by making a taper in the larger proximal thoracic device and attaching it to a smaller distal thoracic device. The Viabahn branches for the visceral vessels are sutured to holes made in the tapered section. The modified Valiant stent graft is advanced to the lesion site endoluminally via the iliac/femoral artery. Access for delivery of extensions to the device will be delivered through the left subclavian artery. Upon deployment, the stent graft self-expands at the target location, where it is designed to exclude the lesion by restoring blood flow through the stent graft lumen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Disease

Currently open trials in the same condition.

NCT07415447 — Cardiac Remodelling Following Endovascular Repair of the Aorta · recruiting
NCT05603520 — Phenotyping Heterogeneity and Regionality of the Aorta · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02524834 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rodney A. White, MD
Last refreshed: 6 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02524834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing